

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number : **0 485 347 A2**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number : **91830479.1**

(22) Date of filing : **04.11.91**

(51) Int. Cl.⁵ : **C12N 15/40, C07K 13/00,
C12P 21/00, G01N 33/576,
C12N 15/62**

(30) Priority : **05.11.90 IT 6786590**

(43) Date of publication of application :
13.05.92 Bulletin 92/20

(84) Designated Contracting States :
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant : **SORIN BIOMEDICA S.p.A.**
Via Crescentino
I-13040 Saluggia (Vercelli) (IT)

(72) Inventor : **Bonelli, Fabrizio**
c/o Sorin Biomedica S.p.A.
I-13040 Saluggia (VC) (IT)
Inventor : **Calogero, Raffaele**
c/o Sorin Biomedica S.p.A.
I-13040 Saluggia (VC) (IT)
Inventor : **Boniolo, Antonio**
c/o Sorin Biomedica S.p.A.
I-13040 Saluggia (VC) (IT)

(74) Representative : **de Simone, Domenico et al**
Ing. Barzanò & Zanardo Roma S.p.A. Via
Piemonte 26
I-00187 Roma (IT)

(54) **Recombinant hepatitis delta antigen, process for the purification and use thereof.**

(57) It is described a composition comprising recombinant HDAg and HDAg-like polypeptides with an antigenicity comparable to the natural molecule expressed in human liver HDV infected cells. It is also described a process for the purification of said molecules and immunoassays for the use thereof.




FIG. 3

EP 0 485 347 A2

Technical field of the invention

This invention relates to Hepatitis Delta Viral antigen (HDAg) expressed from host cells transformed with vectors comprising HDAg coding sequences, to a process for the purification thereof in an antigenic form and to its use in the diagnostic field. More specifically, the invention relates to HDAg-like polypeptides expressed from recombinant vectors wherein the expressed polypeptide functions in diagnostic and therapeutic applications in a manner characteristic of the HDAg polypeptide found within liver cells infected with the Hepatitis Delta Virus (HDV).

Background art

HDV is a major human pathogen that was discovered by Rizzetto and coworkers in Hepatitis B Virus (HBV)-infected patients experiencing severe liver disease (Rizzetto et al., Gut, 18:997-1003, 1977). HDV depends on HBV for the provision of a coat and accordingly has only been found in patients also infected with HBV. The HDV genome consists of a circular, single stranded RNA approximately 1.7 kb in length with the ability to fold on itself by intramolecular base pairing to form a double-stranded rod-like structure (Kos et al., Nature 323:558, 1986). Recent studies have demonstrated that HDV replication is independent of the presence of HBV (Taylor et al., J. Virol. 61:2891, 1987).

It has been shown that an antigenic protein, denominated HDAg is encoded by one of the HDV open reading frames (ORF5) and results to be indispensable for replication of the HDV genome. The identification and partial characterization of ORF5 is described in the EP Applications No. 0234050 and No. 0251575. The activity of ORF5 can be supplied in trans, by the diffusible HDAg and does not necessarily require the physical proximity of ORF5 to the replication control regions of the virus. The role of HDAg has been studied extensively with respect to its role in viral replication (Luo et al., J. Virol. 64:1021, 1990; Hsieh et al., J. Virol. 64:3192, 1990; Chao et al., J. Virol. 64:5066, 1990). HDAg has been found to exist in a 24 kd form and a 27 kd form (Bergmann et al., J. Infect. Dis. 154:702, 1986), with the larger form (214 amino acids) representing a 19 amino acid carboxyl-terminal extension of the smaller (195 amino acids) form (Taylor, Cell 61:371, 1990). The larger form which may actually inhibit viral replication (Taylor, *supra*) may arise from conversion of a UAG termination codon for the smaller HDAg to UGG, permitting synthesis of the larger variant polypeptide (Luo et al., *supra*; Taylor, *supra*).

The diagnosis of HDV infection is usually established by detection of corresponding total and/or M (IgM) immunoglobulins directed against HDAg. To detect anti-HDAg immunoglobulin activity various blocking and competitive inhibition enzyme immunoassays have been developed (Crivelli et al., J. Clin. Microbiol. 14:173, 1981; Purcell and Gerin, Virology, 2nd Ed., Fields et al. Eds., 2275-2283, 1990; Farci et al., J. Am. Med. Assoc. 255:1443, 1986). All of these immunoassays make use of the natural antigen that can be extracted from human- or chimpanzee-infected liver. Unfortunately, the natural antigen is present in the hepatocytes at very low concentration and is extremely unstable under the relatively harsh conditions that may accompany isolation and purification of the antigen (e.g., 6M guanidinium HCl, 8M urea). Such instability may lead to formation of relatively low molecular weight peptides with reduced immunodiagnostic or immunotherapeutic utility compared to a full-length or nearly full-length HDAg.

A high level of expression of recombinant polypeptides in E.coli frequently results in formation of cytoplasmic granules observable with a phase-contrast microscope. Such insoluble granules have been termed "inclusion bodies", and are thought to represent macromolecular complexes of the heterologous polypeptide and the bacterial outer membrane (Frankel et al., Proc. Natl. Acad. Sci USA 88:1192, 1991). The inclusion bodies frequently are used as a source of expressed polypeptide, since the inclusion bodies are readily pelleted by centrifugation and provide a convenient source of polypeptide. However, to obtain soluble protein, the inclusion bodies must be solubilized under relatively harsh conditions such as 5-7 M guanidine HCl, 6-8 M urea, sodium dodecyl sulfate (SDS), alkaline pH, and/or acetonitrile/propanol. Thus, isolation of recombinant HDAg or HDAg-like polypeptides from inclusion bodies yields peptides having reduced immunodiagnostic and immunotherapeutic utility in comparison to native HDAg or to expressed HDAg.

Disclosure of the invention

Figure 1 shows a restriction map of pSORF5.

Figure 2 shows a restriction map of pHbc27.

Figure 3 shows a restriction map of pSORIN δ .

Vector construction generally employs techniques now well understood by those skilled in the art. Site-specific DNA cleavage is performed by means of suitable restriction enzymes under conditions generally speci-

fied by the manufacturer of commercially available restriction enzymes (see for example the New England Biolabs Product Catalogue). Sticky end cleavage fragments may be blunt ended using E.coli DNA polymerase 1 (Klenow fragment) in the presence of appropriate deoxynucleotide triphosphates (dTNPs) using incubation conditions appropriate to the polymerase. The polymerase fills in 5' protruding ends. Alternatively, treatment with S1 nuclease may be used, with resultant hydrolysis of any single stranded DNA portion. Ligations, whether with sticky ends or blunt ends, are carried out using standard buffer and temperature conditions with T4 DNA ligase. Vector fragments are often treated with bacterial alkaline phosphatase in order to remove the 5' phosphate and thus prevent religation of the vector. Ligation mixtures may be transfected into suitable hosts, such as E.coli, and successful transformants selected by antibiotic resistance or other appropriate means, then screened for the correct orientation of insert.

The term transformation includes, without limitation, known methods for transformation of host cells by nucleic acid uptake, microinjection, electrotransformation, electroporation, pellet bombardment or any other suitable method for transfer of exogenous nucleic acid into host cells (see, e.g. Sambrook et al., Molecular Cloning A. Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, 1989).

In contrast to isolation of expressed polypeptides from the commonly used inclusion bodies, applicants have discovered in particular that undenatured HDAg-like polypeptide may be isolated in multimeric form from the cytosolic fraction of bacterial cells using a simple one-step ultracentrifugation procedure. This particular discovery may be generalized as follows. As used herein, the terms "cytosol" or "cytosolic fraction" refer to prokaryotic or eukaryotic cell cytoplasm exclusive of membranes and membrane-bound organelles. That is, the cytosol or cytosolic fractions is defined by the intracellular regions between membrane-bounded organelles. Polypeptides in the cytosol generally constitute "soluble" polypeptides, though such polypeptides may exist in monomeric or multimeric forms and may be capable of organizing as aggregates or particles when in the multimeric form. Such cytosolic aggregates, however, require relatively high-speed centrifugation for purification and generally do not co-purify with membrane-bound organelles or other cellular structures, such as inclusion bodies, which are readily pelleted by low speed centrifugation.

The invention involves the finding that multimeric aggregates of HDAg recombinant polypeptide have an antigenicity substantially comparable to the antigenicity of HDAg antigen of HDV-infected human liver cells. The aggregate is recovered from host cells which have been transformed with a recombinant vector able to express HDAg polypeptide. The aggregate may further contain HDV RNA bound to the polypeptide. In the case where the host cells are bacterial cells, the aggregates may be recovered by separating such aggregates from cell membrane material and cell inclusion bodies resulting, from sonication or any other method of disrupting the bacteria. This separation of aggregate from cell membrane material and cell inclusion bodies may be accomplished by centrifugation. Subsequent to the separation by centrifugation, the aggregates may also be separated substantially from cytosolic material by ultracentrifugation such as sucrose gradient fractionation.

The present invention solves the problems referred to by providing recombinant DNA molecules able to express after transformation in a suitable host recombinant HDAg with an antigenicity substantially comparable to the antigenicity of HDAg of HDV from infected human liver cells. The present invention provides also a process for the purification of the HDAg with an antigenicity substantially comparable to the antigenicity of HDAg of HDV from infected human liver cells and its use in the diagnostic field.

In a preferred embodiment, the host cells may be transformed with a recombinant expression vector carrying the coding information for HDAg-like recombinant polypeptides, containing a first region substantially homologous to substantially intact HDV antigen and an amino terminal second region contiguous to the first region and a carboxyl terminal third region contiguous to the first region, wherein the first region is HDAg antigenic and the second region and third region are each substantially heterologous to HDV antigen. The second region and third region may each be coded by nucleic acid sequences substantially heterologous to related HDV RNA. Where the host cells are bacterial cells, preferably E.coli, the aggregates may be recovered by separating the aggregates from cell membrane material and cell inclusion bodies and subsequently separating the aggregates from the cytosol of disrupted host cells by either ultracentrifugation on sucrose gradient or sequential immunoaffinity chromatography specific to the second region and third region. Preferably said second region comprises a region from the E. coli beta-galactosidase coding region and said third region comprises a coding region from pBR322 plasmid. According to a preferred embodiment, the HDAg-like recombinant polypeptide is, or is substantially homologous to, B-HDAg-T, whose aminoacid sequence is shown in Table 1.

Table 1 Nucleic acid and amino acid sequences of

B-HDAg-T (-): beta-galactosidase; (_): linker; (>):

HDAg; (*): pBR322 tet gene

[illegible]

[illegible]

550 560 570 580 590 600
| | | | |
CCCAGTCTGCAGGGGACTCCCGGAGTCCCCCTTCTCTCGGACCGGGGAGGGGCTGGACATC

5
P S L Q G V P E S P F S R T G E G L D I
>>

610 620 630 640 650 660
| | | | |
AGGGGA AACCGGGATTTC CATGGGATACTCTTCCCAGCCGATCCGCCCTTTTCTCCC

10
R G N R G F P W D I L F P A D P P F S P
>>

670 680 690 700 710 720
| | | | |
CAGAGGGGTCTCTACGCCGGAGCCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGT

15
Q R G P L R R S H R G R H H R R H R C G
>> *****

730 740 750 760 770 780
| | | | |
TGCTGGCGCCTATATCGCGGACATCACCGATGCGGAAGATCGGGCTCGCCACTTCGGGCT

20
C W R L Y R R H H R C G R S G S P L R A

790 800 810 820 830 840
| | | | |
CATGAGCGCTTGTTTTCGGCGTGGGTATGGTGGCAGGCCCGTGGCCGGGGGACTGTTGGG

25
H E R L F R R G Y G G R P R G R G T V G

850 860 870 880 890 900
| | | | |
CGCCATCTCCTTGCA TGACCATT CCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACT

30
R H L L A C T I P C G G G A Q R P Q P T

910 920 930
| | |
ACTGGGCTGCTTCTTAATGCAGGAGTCGCATAA

35
T G L L L N A G V A -

40
45

50 According to the present invention a method is furnished to allow expression of a nearly full-length HDAG and recovery of the expressed polypeptide under conditions substantially preserving the conformational epitopes of the antigen, preferably without use of denaturing agents, said HDAG having an antigenicity comparable to the intact natural antigen present in infected human or chimpanzee liver cells in the sense that the recombinant HDAG-like polypeptide is cross-reactive with and has a similar affinity index as the naturally derived
55 HDAG. Thus, the recombinant HDAG-like polypeptide of the present invention is particularly useful in immunoassay of the HDAG in body tissue and fluids or antibodies in serum specific to such HDAG. The recombinant HDAG-like polypeptide is useful as a standard for such assays as well as other reagents as more fully discussed below.

In a preferred embodiment of the invention the HDAq-like polypeptide is encoded by an expression vector

containing appropriate expression and other control elements as well as sequence encoding all but the carboxyl-terminal six amino acids of the large form of HDAg. In a specific embodiment of the invention the said expression vector is the plasmid pSORIN δ , deposited at DSM N. 6774.

According to this embodiment of the invention, E.coli cells expressing HDAg-like polypeptide from pSORIN δ are centrifuged to form a cell paste, resuspended in lysis buffer, and sonicated under conditions generally disrupting the outer bacterial membrane while generally leaving the inclusion bodies intact. Any other known method for disruption of cells while leaving intact the inclusion bodies may be employed without departing from the scope of the present invention. Following cellular disruption, the cellular membranes, inclusion bodies and other cellular debris were pelleted by low speed centrifugation (e.g. 10.000 rpm in a JA17 Beckman rotor for 30 min. at 4.C). The supernatant containing the cytosolic fraction with soluble polypeptides is applied to the top of a 10-50% sucrose gradient and subjected to a 16-hour ultracentrifugation run. Thereafter, the expressed HDAg-like polypeptide is isolated from the bottom of the gradient in the form of multimeric aggregates. While the HDAg-like polypeptide isolated from sucrose gradients is eminently suited to immunodiagnostic and other applications, it is to be understood that other centrifugation media known to those skilled in the art, such as caesium sulfate and caesium chloride, may be employed for ultracentrifugation of HDAg-like polypeptide multimers.

As an alternative to isolation of HDAg-like polypeptide by ultracentrifugation, the HDAg-like polypeptide may be purified by immunoaffinity chromatography. The applicants have developed a double column procedure that exploits polypeptide sequence, heterologous to ORF5, that is contiguous with the ORF5 amino acid sequence at the amino terminal and carboxyl terminal portions of the expressed polypeptide. That, is, a monoclonal antibody (MAB-B) was raised to the non-ORF5 amino terminal portion of the expressed polypeptide. In like manner, a monoclonal antibody (MAB-T) was raised to the non-ORF5 carboxyl terminal portion of the expressed polypeptide. MAB-B was used on a first immunoaffinity column, and MAB-T was used on a second immunoaffinity column.

The same cellular lysate material as was applied to the top of the sucrose gradients was applied to the first immunoaffinity column. The MAB-B-bound material was eluted and applied to the second column. Only expressed polypeptide having both amino-terminal and carboxyl-terminal portions recognized by MAB-B and MAB-T, respectively, will be retained by the second column. Such polypeptide material will include the entire ORF5 encoded by pSORIN δ , since the ORF5 amino acid sequence is located between the heterologous amino acid sequences recognized by MAB-B and MAB-T. Following elution from the second column, the expressed polypeptide may be employed in a variety of immunodiagnostic and immunotherapeutic applications.

The purified expressed HDAg-like polypeptide is useful in a variety of immunoassay formats well known in the art. The invention includes use of the purified multimeric aggregates as described above for detection of analyte antibodies or analyte antigens in patient samples. As an illustration, analyte antibodies may be detected such as total immunoglobulin (Ig) or as immunoglobulin M (IgM).

As an example of immunoassay for anti-HDAg Ig, microtiter plates may be coated with MAB-T using standard procedures. The expressed polypeptide then may be added to the plates under conditions promoting binding of the polypeptide to MAB-T. Having attached the expressed HDAg-like polypeptide to the solid phase, patient serum and enzyme-labelled anti-HDAg polyclonal antibody may be added to the plates in a competitive immunoassay format well known to those skilled in the art. The amount of enzyme-labelled anti-HDAg polyclonal antibody bound to the plate is a measure of the amount of anti-HDAg Ig in the serum sample. In an alternative embodiment, biotinilated HDAg may be bound to the solid phase via streptavidin.

As an illustration of immunoassay for anti-HDAg IgM, microtiter plates may be coated with anti-human IgM monoclonal antibody according to standard methods. Patient serum is then added to the plate to sequester patient IgM to the solid phase. These solid phase patient IgM antibodies are then reacted simultaneously or sequentially with HDAg-like polypeptide and with enzyme-labelled anti-HDAg polyclonal antibody. The amount of enzyme label that becomes bound to the solid phase is a measure of the amount of anti-HDAg IgM in the patient sample. In an alternative embodiment, enzyme-labelled MAB-T may be used in place of the enzyme-labelled anti-HDAg polyclonal antibody.

Detection of analyte HDAg in a patient sample may be accomplished with a microtiter plate or other solid phase having attached an anti-HDAg antibody. Patient sample is added to the plate for reaction. The solid phase bound HDAg from the patient sample is then reacted with a labelled anti-HDAg antibody.

Detection of analyte HDAg in a patient sample may also be accomplished in any of the competitive binding immunoassay formats known to those skilled in the art, utilizing the purified HDAg polypeptide as described above. In such formats, HDV antigen present in the patient sample competes with the expressed HDAg-like polypeptide for binding to an anti-HDAg antibody.

The following examples are intended to illustrate but not to limit the invention.

EXAMPLE 1 Construction of Plasmid pSORF5

Total RNA from a biopsy of HDV-infected human liver was extracted as described (Chirgwin, Biochemistry 18:5294, 1979). A 20 ug sample of this RNA was analyzed in Northern blot format (Thomas, Proc. Natl. Acad. Sci. 77:5201, 1980), by hybridization to the oligonucleotide probe M316 (3' CGA ACG GAC CAG ATG GAG GTA GAC TCC GGA CCT AGG AAG AG 3') (data not shown). 18 ug of total RNA were used as template for first strand cDNA synthesis as described (Sambrook et al., *supra*), using as primer the oligonucleotide M314 (5' ATG AGC CGG TCC GAG TCG AGG AAG 3'). The cDNA reaction mixture was used in PCR amplification experiments (Kawasaki, In: Innis et al., eds., PCR Protocols; A Guide to Methods and Applications, Academic Press, pp. 21-27), using as primers the oligonucleotides M314 and M315 (5' TCA CTG GGG TCG ACA ACT CTG GGG AGA 3'). The PCR amplification was performed with a protocol of 35 cycles, each cycle consisting of one min. at 95C, one min. at 50C, and three min. at 65C. The amplification reaction produced two major bands: one of 300 bp and the other of 640 bp (data not shown). Southern blot analysis revealed that only the 640 bp band hybridized with oligonucleotide M316 (data not shown).

The 640 bp band (200 ng) was cloned into SmaI-cut pTZ18R (50 ng) (Pharmacia, Sweden) by using an overnight ligation at 15C with 1 Weiss unit of T4 ligase (Promega, WI) in 20 ul 1xT4 ligase buffer (Promega, WI). The ligation mixture (10 ul) was used to transform E.coli strain JM109 cells; competent JM109 cells were prepared as described by Sambrook et al., *supra*. The recombinant plasmid was denominated pSORF5 (Figure 1). The 640 bp insert was sequenced with a Taq polymerase sequencing (Promega, WI).

EXAMPLE 2 Construction of Expression Plasmid pSORINδ

The expression plasmid pHbC27 (Figure 2) was used to provide appropriate transcription and other control elements for expression of HDAg. Any other equivalent expression vector is suitable. pHbC27, a derivative of pBR322, contains sequence encoding the hepatitis B virus (HBV) core antigen (HBcAg), and is described in Stahl et al., Proc. Natl. Acad. Sci. USA 79:1601 (1982). A lac promoter carrying the UV5 mutation (lac UV5 promoter), the ribosomal binding site (RBS) of beta-galactosidase, and sequence encoding the first eight amino acids of beta-galactosidase are located immediately upstream of the EcoR1 site in pHbC27. The BamH1 site in pHbC27 is located within the gene for tetracycline resistance (tet), approximately 350 bases pairs (bp) from the 3' end of the tet gene.

The plasmid HBc27 was cut with EcoR1 and BamH1 and the large fragment (pLac, approximately 4,500 bp) containing transcription and other control elements was purified from the short fragment (1,011 bp) containing the HBcAg sequence. The EcoR1 and BamH1 ends of pLac were filled in (blunt ended) with the Klenow fragment of E.coli DNA polymerase according to standard methods (Sambrook et al., v. *supra*). pSORF5 provided HDAg sequence for expression of HDAg-like polypeptide. A BamH1/RsaI fragment of 627 bp encoding all but the carboxyl-terminal six amino acids of ORF5 was obtained from pSORF5, and blunt ended as described above.

The 627 bp fragment from pSORF5 was cloned into pLac by blunt end ligation (see Sambrook et al., *supra*) and the correct orientation of the ORF5 insert with respect to transcriptional control elements was confirmed by restriction mapping. The resulting plasmid, pSORIN (Fig. 3, Table 2, deposited at DSM No.6774) was used to transform E.coli cells of strain W3 110, and 1.0 ml aliquots of cultures were frozen in 15% glycerol at -70C. E.coli strain W3 110 is deposited with the American Type Culture Collection (ATCC), No. 27325.

Table 2 Nucleic acid sequence of pSORIN .

5

10

[illegible]

(+ LacUV5 promoter)
(0 Bgalactosidase 5&D)
(- orf5 gene + trailer sequence)

15

GGCGATTGATTAAATGCTGSSACGACAGGTTTCCCGACTGSAAGCGGGCA
+++++

20

GTGAGGCGCAACGCAATTAAATGAGTTAGCTCACTCATTAGGCACCCCCAG
 ++++++
 LacUV5 promoter

25

GCTTTACACATTTATGCTTCCATCATCGGCTCGTATAATGTGTGGAATTG
 ++++++

30

TGAGCGGATAACAATTTACACAGGAAACAGCTATGACCATGATTACGGA
 ++++++
 S&D M T M I T D

T T C A C T G G A A T T G A T C C C C A T G A G C C G G T C C G A G T C G A G G A A G A A C C G C G
S L -----

35

GAGGGAGAGAAGAGATCTCGAGCAGTGGGTGGCCGGAAGAAAGAAGTTA

40

45

50

55

5

E
C
O
R
I

10

A
P
a
I

15

500

20

25

30

S P
m s
a t
I I

35

40

45

50

55

1000

CBTGGCCGGSSGACTGTTGGGCGCCATCTCCTTGCAATGCACCATTCCTTG

 5 CGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCTTAATG

 CAGGAGTCGCATAAGATCCTCTACGCCGGACGCAATCGTGGCCGGCATCAC

 10 CGGCGCCACAGGTGCGGTGCTGGCGCCTATATCGCCGACATCACCAGTG

 GGGAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTCGGCGTG
 15
 GGTATGGTGGCAGGCCCGTGGCCGSSGAGTGTGGGCGCCATCTCCTT
 20
 GCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTAC

 TGGGCTGCTTCCTAATGCAGGAGTCGCATAAGSSASAGCGTCGACCGATG
 25
 CCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCGGSTGGSCGCGGSCAT
 30
 GACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAG 1500
 35
 GACAGGTGCCGGCAGCGCTCTGGGTCAATTTTCGGCGAGGACCGCTTTCGC

 TGSAGCGCGACGATGATCGGCCCTGTCGCTTGCGGTATTCGGAATCTTGCA
 40
 CGCCCTCGCTCAAGCCTTCGTCCTGGTCCCGCCACCAACGTTTCGGCG
 45
 AGAAGCAGGCCATTATCGCCGGCATGGCGGCGGACGCGCTGGGCTACGTC

 TTGCTGGCGTTTCGCGACGCGAGGCTGGATGGCCTTCCCCATTATGATTCT
 50
 TCTCGCTTCCGGCGGCATCGGATGCCCGCGTTGCAGGCCATGCTGTCCA
 55

GGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGATCGCTCGCGGCT
 5 CTTACCAGCCTAACTTCGATCACTGGACCGCTGATCGTCACGGCGATTTA
 10 TGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATGGATTGTAGGCGCCG
 15 CCTATACCTTGCTCGCTCCCCGCGTTGCGTCGCGGTGCATGGAGCCGG 2000
 GCCACCTCGACCTGAATGGAAGCCGGCGGCACCTCGCTAACGGATTACCC
 20 ACTCCAAGAATTGGAGCCAATCAATTCTTGGGAGAACTGTGAATGCGCA
 25 AACCAACCCCTTGGCAGAACATATCCATCGCGTCCGCCATCTCCAGCAGCC
 30 GCACGCGGCGCATCTCGGGCAGCGTTGGGTCTTGGCCACGGGTGCGCATG
 35 ATCGTGCTCCTGTCGTTGAGGACCCGGCTAGGCTGGCGGGGTTCCTTAC
 TGGTTAGCAGAATGAATCACCGATACGCGAGCGAACGTGAAGCGACTGCT
 40 GCTGCAAAACGTGTGCGACCTGAGCAACAACATGAATGGTCTTCGGTTTC
 45 CGTGTTTCGTAAAGTCTGGAAACGCGGAAGTCAGCGCCCTGCACCATTAT
 50 GTTCGGATCTGCATCGCAGGATGCTGCTGGCTACCCTGTGGAACACCTA
 55

CATCTGTATTAAACGAAGCGCTGGCATTGACCCCTGAGTGATTTTTCTCTGG 2500

5 TCCCGCCGCATCCATAACCGCCAGTTGTTTACCCCTCACAAACGTTCCAGTAA

10 CCGGGCATGTTTCATCATCAGTAACCCGTATCGTGAGCATCCTCTCTCGTT

15 TCATCGGTATCATTACCCCCATGAACAGAAATTCCCCCTTACACGGAGGC

20 ATCAAGTGACCAACAGGAAAAACCGCCCTTAACATGGCCCGCTTTATC

25 AGAAGCCAGACATTAAACGCTTCTGGAGAACTCAACGAGCTGGACGCGGA

30 TGAACAGGCAGACATCTGTGAATCGCTTCACGACCACGCTGATGAGCTTT

P

V

U

2

35 ACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACAC

40 ATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAAGCGGATGCCGGGAG

45 CAGACAAGCCCGTCAGGGCGCGTCAACGGGTGTTGGCGGGTGTGCGGGCG

50 CAGCCATGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAACT 3000

R

S

a

I

55 ATGCGGCATCAGAGCAGATTGTACTGAGAGTGACCATATGCGGTGTGAA

ATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCGCG

55

TTCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCCGGCTCCGGCGAGCGG
 5
 TATCAGCTCACTCAAAGGCGGTAAATACGGTTATCCACAGAATCAGGGGAT
 10
 AACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCG
 15
 TAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACG
 AGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA
 20
 CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCCTCTCC
 25
 TGTTCCGACCCCTGCCGCTTACCGGATACCTGTCCGCCCTTCTCCCTTCGG
 30
 GAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTG 3500
 35
 TAGGTCGTTCCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTACGCC
 CGACCGCTGCCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAA
 40
 GACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGA
 45
 GCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAAGTGGTGGCCTAACTA
 50
 CGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAG
 55

TTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAACCACC
5 GCTGGTAGCGGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAA
10 AAAAGGATCTCAAGAAGATECCTTTGATCTTTTCTACGGGGTCTGACGCTC
AGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAA
15 AGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAAT 4000
20 CTAAAGTATATATGAGTAACTTGGTCTGACAGTTACCAATGCTTAATCA
25 GTGAGGCACCTATCTCAGCGATCTGTCTATTTGTTTCATCCATAGTTGCC
30 TGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGG
CCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATT
35 TATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCT
40 GCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAG
45 AGTAAGTAGTTCCGCCASTTAATAGTTTGCACAACGTTGTTGCCATTGCTG
P
S
50 t
I
CAGGCATCGTGGTGTACGCTCGTCGTTTGGTATGGCTTCATTTCAGCTCC
55

GGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAA

5 AGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAAGTAAGTTGGCCG 4500

10 CAGTGTTATCACTCATGTTATGGCAGCACTGCATAATTCTCTTACTGTC

15 ATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTC

20 ATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAA

25 CACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATT

30 GGAAAACGTTCTTCGGGGCGAAACTCTCAAGGATCTTACCGCTGTTGAG

35 ATCCAGTTCGATGTAACCCACTCGTGACCCCACTGATCTTCAGCATCTT

40 TTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCCAAAATGCC

45 GCAAAAAAGGGAATAAGGCCGACACGGAAATGTTGAATACTCATACTCTT

50 CCTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCG

55 GATACATATTTGAATGTATTTAGAAAAATAACAATAGGGGTTCCGCGC 5000

ACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCAT

GACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAA

Given the structure of pSORIN δ , the polypeptide expected to be expressed from pSORIN δ consists of

the amino acid sequence shown in Table 1, beginning with the amino terminal portion and progressing to the carboxyl terminal portion of the polypeptide: a) eight amino acids derived from beta galactosidase, b) four amino acids derived from linker sequence used in construction of the respective plasmids, c) 209 amino acids derived from ORF5 (HDAg) and d) 09 amino acids derived from the tet gene of pBR322. The eight amino acids derived from beta-galactosidase are hereinafter termed the "B" region of the expressed polypeptide. The 89 amino acids derived from the tet gene, expected to display a secondary structure including "turn" and "extended" regions, is hereinafter termed the "T" or "trailer" region. The full-length expressed polypeptide therefore comprises B, HDAg and T amino acids, and is hereinafter termed the "B-HDAg-T" polypeptide and is the preferred form of HDAg-like polypeptide.

EXAMPLE 3 Growth of Cells Transformed with pSORIN δ

A 1 ml frozen aliquot of stock E.coli strain W3 110 transformed with pSORIN was thawed and grown at 37C for 16 hours in Luria-Bertani broth with 50 ug/ml ampicillin. The overnight culture was inoculated into a 14-liter working volume fermenter (Chemag, F23000) and grown under the following constant conditions:

- a) Stirring rate: 400 rpm.
- b) Air flow rate: 2 liters/min.
- c) temperature: 37C.
- d) pO₂: 60%.
- e) pH: 7.4.

The bacterial growth was monitored at 590 nm. When the culture had attained an optical density (OD) of 0.5, isopropyl-B-D-galactoside (IPTG) was added to the culture at a final concentration of 1.0 mM in order to induce expression of B-HDAg-T under control of the lac UV5 promoter. Thereafter, the temperature was reduced to 30C and the stirring rate was increased to 1,300 rpm. The cells were harvested three hours post-induction with IPTG by pelleting at 3,000xg for 10 min. at 4C.

EXAMPLE 4 Purification of B-HDAg-T Polypeptide by Sucrose Density Gradient Centrifugation

Pelleted E.coli cells as described above were resuspended in 50 mM Tris/HCl pH 8.0, 1.0 mM EDTA, 1.0 mM FMSF and 100 mM NaCl, then disrupted by sonication (Braun Labsonic Model 1510 sonicator; three bursts of 60 sec. each at 100W, on ice). Following sonication, 8.0 mg/ml of sodium deoxycholate were then added at 4C under mixing. The cellular membranes, inclusion bodies and other cellular debris were removed by pelleting at 10,000 rpm in a JA17 Beckman rotor for 30 min. at 4C. The supernatant was loaded on a 10-50% sucrose gradient made with 50 mM Tris/HCl pH 7.5 and the gradient centrifuged at 35,000 rpm in a 5W40 TI Beckman rotor, for 16 hours at 4C. Contents of the gradient were recovered at a flow rate of 0.8 ml/min. and collected as 0.4 ml fractions. The B-HDAg-T polypeptide was found at the bottom of the gradient in the form of multimeric aggregates. The purity of the B-HDAg-T material from the gradient is estimated at 85-90% based on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) and staining of polypeptide bands with Coomassie brilliant blue dye. In other words, no more than 10-15% non-B-HDAg-T polypeptide is present in the isolated fractions taken from the bottom of the gradient.

A sample of the B-HDAg-T polypeptide material obtained from sucrose gradients as described above was stained with uranyl acetate and examined with electron microscopy. The multimeric forms of HDAg obtained from the sucrose gradients are generally larger than 10. daltons. The multimeric aggregates consist of nucleoprotein complexes of B-HDAg-T and RNA. It is known that HDAg is capable of binding to RNA. Chang et al., J. Virol. 62:2403 (1988). Further, the applicants have observed that sedimentation of HDAg particles (aggregates) is not observed if the E.coli lysate is treated with RNAase prior to loading on the sucrose gradient (data not shown).

EXAMPLE 5 Purification of B-HDAg-T Polypeptide by immunoaffinity Chromatography

As an alternative to purification of B-HDAg-T by sucrose gradient centrifugation, a double immunoaffinity column procedure was developed allowing selection specifically of full-length B-HDAg-T polypeptide. The first immunoaffinity column comprised Sepharose-CNBr (Pharmacia, Sweden) coupled with a monoclonal antibody raised against the...-galactosidase (B) region of B-HDAg-T according to standard techniques (MAB-B). Coupling of antibody to the Sepharose-CNBr was performed according to the procedures recommended by Pharmacia, with a coupling yield in excess of 95%. The second immunoaffinity column comprised Sepharose-CNBr coupled with a monoclonal antibody raised against the T region of the B-HDAg-T polypeptide, according to standard techniques (MAB-T). Specifically, MAB-T is specific for the sequence WRLYRRH present in the T

region of B-HDAg-T.

The same material as was applied to the top of the sucrose gradients, i.e., the crude sonicated lysate following centrifugation at 10,000 rpm for 10 min. at 4°C as described above, was applied to the immunoaffinity column containing MAB-B coupled with Sepharose-CNBr. MAB-B-bound material was eluted with high salt buffer comprising 3.5M MgCl₂, 10 mM phosphate pH 7.2, then dialysed twice against 1 liter of phosphate buffered saline (PBS). The eluted material was then applied to the second immunoaffinity column containing MAB-T and eluted again with high salt buffer. The material eluted following the second immunoaffinity purification was determined to be full-length B-HDAg-T of 98% purity as determined by SDS PAGE and Coomassie Blue staining.

EXAMPLE 6 Competitive Immunoassay for Total Immunoglobulin (Ig) Anti-HDAg

Microtiter plates were coated with MAB-T (anti-WRLYRRH) using standard procedures. Then HDAg in the form of the expressed and sucrose gradient-purified B-HDAg-T polypeptide as described above were added to the plates at a concentration of 0.2 ug/ml. The plates that had been coated with B-HDAg-T were incubated at room temperature for 18 hours, then washed with BPS. Following washing, the plates were suitable for use in determination of total Ig anti-HDV in blood sera.

Each well of the microtiter plates treated as above received 10 ul of serum to be analyzed. Immediately following addition of test serum, an anti-HDAg polyclonal antibody preparation labelled with horseradish peroxidase (HRP) was added to each well. Following three hours of incubation at 37°C, the reagents were washed out and the quantity of anti-HDV polyclonal antibody bound to the plate was observed by addition of H₂O₂ and tetramethylbenzidine. The colorimetric reaction was stopped with 1.0 M sulfuric acid and the absorbance at 450 nm and 630 nm was measured. In this competitive assay format, the amount of anti-HDAg polyclonal antibody bound to the microtiter plate, as measured by the colorimetric reaction with HRP, is inversely proportional to the amount of anti-HDAg antibody in the serum sample.

EXAMPLE 7 Immunoassay for Determination of IgM anti-HDV

Microtiter plates were coated with anti-human IgM monoclonal antibody according to standard methods. Sera to be tested (10 ul) were added to the plate wells and incubated for one hour at 37°C. Following this, anti-HDAg polyclonal antibody labelled with HRP and the expressed, sucrose gradient-purified B-HDAg-T polypeptide as described above were added to the plates and incubated for two hours at 37°C. Following this incubation, the unbound reagents were removed by washing and the quantity of HRP-labelled antibody bound to the plates was observed by performing the colorimetric reaction as described above.

Claims

1. A composition comprising a multimeric aggregate, said multimeric aggregate comprising recombinant polypeptides, said aggregates having an antigenicity substantially comparable to the antigenicity of the HDAg of HDV infected human liver cells, said aggregate recovered from host cells which have been transformed to express said polypeptide.
2. The composition according to claim 1 wherein the aggregate further comprises RNA bound to said polypeptide.
3. The composition according to any of the previous claims wherein the host cells are bacterial cells and the recovery of said aggregate from said host cells comprises separating such aggregates from cell membrane material and cell inclusion bodies.
4. The composition according to claim 3 wherein said bacterial cells belong to *E. coli* species.
5. The composition according to any of the previous claims wherein said cells are disrupted by sonication prior to said separation.
6. The composition according to any of the claims from 3 to 5 wherein the aggregates are separated from cell membrane material and cell inclusion bodies by centrifugation.

7. The composition according to any of the claims from 3 to 6 wherein the recovery of said aggregates from said host cells further comprises substantially separating such aggregates from cytosolic material by ultracentrifugation.
- 5 8. The composition according to claim 7 wherein said ultracentrifugation comprises sucrose gradient fractionation.
9. The composition according to any of the previous claims wherein said host cells are transformed with a recombinant vector able to express a polypeptide comprising a first region substantially homologous to substantially intact HDAg.
- 10 10. The composition according to claim 9 wherein said polypeptide further comprises an amino terminal second region contiguous to said first region and a carboxyl terminal third region contiguous to said first region, wherein said first region is HDAg antigenic and said second region and third region are each substantially heterologous to HDAg.
- 15 11. The composition according to claim 10 wherein said second region and third region are each coded by sequences substantially heterologous to related HDV RNA.
- 20 12. The composition according to claim 11 wherein the host cells are E.coli and the recovery of said aggregates from said host cells comprises separating said aggregates from cell membrane material and cell inclusion bodies and subsequently separating said aggregates from the cytosol of disrupted host cells by sequential immunoaffinity chromatography specific to said second region and third region.
- 25 13. The composition according to claim 12 wherein said polypeptide is substantially homologous to B-HDAg-T.
14. The composition according to claim 13 wherein said polypeptide is B-HDAg-T.
15. An immunoassay kit comprising as a reagent the composition according to any of the claims from 1 to 14.
- 30 16. A method of immunoassay of an analyte antibody in a sample comprising binding the analyte antibody specific to the HDAg with the composition of any of claims from 1 to 14, determining the extent of such binding and correlating the extent of such binding to the presence or amount of such analyte antibody in the sample.
- 35 17. A method of immunoassay of analyte antigen in a sample comprising competitive binding of antibody specific to the HDAg with the analyte antigen and the composition of any of claims from 1 to 14, determining the extent of such competitive binding with the analyte antigen and said composition and correlating the extent of such competitive binding to the presence or amount of such analyte antigen in the sample.
- 40 18. A method of immunoassay of analyte in a sample comprising binding an immunoreactive substance with a standard comprising the composition of any of claims from 1 to 14 in order to determine a correlation for similar binding of the analyte.
- 45 19. A process of recovering multimeric aggregate, said multimeric aggregate comprising recombinant polypeptide from E.coli host cells which have been transfected to express said polypeptide, said recovered aggregate having an antigenicity substantially comparable to the antigenicity of the HDAg of HDV infected human liver cells, comprising separating said aggregates from cell membrane material and cell inclusion bodies.
- 50 20. The process according to claim 19 wherein said host cells are disrupted by sonication prior to said separation.
21. The process according to claim 20 wherein the aggregates are separated from cell membrane material and cell inclusion bodies by centrifugation.
- 55 22. The process according to any of claims from 19 to 21 further comprising separating said aggregates substantially from cytosolic material by ultracentrifugation.

23. The process according to claim 22 wherein said ultracentrifugation comprises sucrose gradient fractionation.
24. The process according to any of claims from 19 to 23 wherein said host cells are transfected to express a polypeptide comprising a first region substantially homologous to substantially intact HDAg.
25. The process according to claim 24 wherein said polypeptide further comprises an amino terminal second region contiguous to said first region a carboxyl terminal third region contiguous to said first region, wherein said first region is HDAg antigenic and said second region and third region are each substantially heterologous to HDAg.
26. The process according to claim 25 wherein said second region and third region are each coded by sequences substantially heterologous to related HDV RNA.
27. The process according to claims 25 or 26 wherein said aggregates are separated from the cytosol of disrupted host cells by sequential immunoaffinity chromatography specific to said second region and third region.
28. A composition comprising nucleic acid encoding for B-HDA-T.




FIG. 1




FIG. 2




FIG. 3